Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BTK | Q06187 | 2/20 | 0.57 |
| ▸ | ITK | Q08881 | 2/20 | 0.57 |
| ▸ | MAP4K1 | Q92918 | 1/20 | 0.49 |
| ▸ | KIT | P10721 | 6/20 | 0.46 |
| ▸ | CAMKK2 | Q96RR4 | 2/20 | 0.45 |
| ▸ | PLK4 | O00444 | 1/20 | 0.45 |
| ▸ | NTRK1 | P04629 | 2/20 | 0.45 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.45 |
| ▸ | MAP3K11 | Q16584 | 2/20 | 0.43 |
| ▸ | NEK1 | Q96PY6 | 2/20 | 0.43 |
| ▸ | TDO2 | P48775 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15799721 | 0.92 | BTK (0.59) | BTKITKMAP4K1KITCAMKK2 | |
| SCHEMBL17636840 | 0.85 | BTK (0.41) | BTKITKMAP4K1PLK4PIK3CA | |
| SCHEMBL15805443 | 0.85 | BTK (0.62) | BTKITKKITCAMKK2PLK4 | |
| SCHEMBL15805441 | 0.82 | BTK (0.59) | BTKITKKITCAMKK2PLK4 | |
| SCHEMBL15805501 | 0.82 | CAMKK2 (0.46) | BTKITKMAP4K1CAMKK2PLK4 | |
| SCHEMBL17636849 | 0.79 | BTK (0.43) | BTKITKMAP4K1PLK4NTRK1 | |
| SCHEMBL15805374 | 0.79 | PTPN11 (0.41) | BTKITKPIK3CA | |
| SCHEMBL12763087 | 0.76 | BTK (0.60) | BTKITKKITPLK4NTRK1 | |
| SCHEMBL15799619 | 0.76 | BTK (0.63) | BTKITKKITCAMKK2PLK4 | |
| SCHEMBL19670830 | 0.76 | BTK (0.80) | BTKITKKITNTRK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9951062-B2 | Substituted 1 H-pyrrolo [2, 3-b] pyridine and 1 H-pyrazolo [3, 4-b] pyridine derivatives as salt inducible kinase 2 (SIK2) inhibitors | ARRIEN PHARMACEUTICALS LLC (US) | 2018-04-24 | — | — | US | disclosed |
| US-9951062-B2 | Substituted 1 H-pyrrolo [2, 3-b] pyridine and 1 H-pyrazolo [3, 4-b] pyridine derivatives as salt inducible kinase 2 (SIK2) inhibitors | ARRIEN PHARMACEUTICALS LLC (US) | 2018-04-24 | — | — | US | disclosed |
| US-9951062-B2 | Substituted 1 H-pyrrolo [2, 3-b] pyridine and 1 H-pyrazolo [3, 4-b] pyridine derivatives as salt inducible kinase 2 (SIK2) inhibitors | ARRIEN PHARMACEUTICALS LLC (US) | 2018-04-24 | — | — | US | disclosed |
| US-9890153-B2 | Substituted 1H-pyrrolo [2, 3-b] pyridine and 1H-pyrazolo [3, 4-b] pyridine derivatives as salt inducible kinase 2 (SIK2) inhibitors | ARRIEN PHARMACEUTICALS LLC (US) | 2018-02-13 | — | — | US | disclosed |
| US-9890153-B2 | Substituted 1H-pyrrolo [2, 3-b] pyridine and 1H-pyrazolo [3, 4-b] pyridine derivatives as salt inducible kinase 2 (SIK2) inhibitors | ARRIEN PHARMACEUTICALS LLC (US) | 2018-02-13 | — | — | US | disclosed |
| US-9890153-B2 | Substituted 1H-pyrrolo [2, 3-b] pyridine and 1H-pyrazolo [3, 4-b] pyridine derivatives as salt inducible kinase 2 (SIK2) inhibitors | ARRIEN PHARMACEUTICALS LLC (US) | 2018-02-13 | — | — | US | disclosed |
| US-20160090382-A1 | Substituted 1 H-Pyrrolo [2, 3-b] pyridine and 1 H-Pyrazolo [3, 4-b] pyridine Derivatives as Salt Inducible Kinase 2 (SIK2) Inhibitors | ARRIEN PHARMACEUTICALS LLC | 2016-03-31 | — | — | US | disclosed |
| US-20160090382-A1 | Substituted 1 H-Pyrrolo [2, 3-b] pyridine and 1 H-Pyrazolo [3, 4-b] pyridine Derivatives as Salt Inducible Kinase 2 (SIK2) Inhibitors | ARRIEN PHARMACEUTICALS LLC | 2016-03-31 | — | — | US | disclosed |
| US-20160090382-A1 | Substituted 1 H-Pyrrolo [2, 3-b] pyridine and 1 H-Pyrazolo [3, 4-b] pyridine Derivatives as Salt Inducible Kinase 2 (SIK2) Inhibitors | ARRIEN PHARMACEUTICALS LLC | 2016-03-31 | — | — | US | disclosed |
| US-20160081989-A1 | Substituted 1 H-Pyrrolo [2, 3-b] pyridine and 1 H-Pyrazolo [3, 4-b] pyridine Derivatives as Salt Inducible Kinase 2 (SIK2) Inhibitors | ARRIEN PHARMACEUTICALS LLC | 2016-03-24 | — | — | US | disclosed |
| US-20160081989-A1 | Substituted 1 H-Pyrrolo [2, 3-b] pyridine and 1 H-Pyrazolo [3, 4-b] pyridine Derivatives as Salt Inducible Kinase 2 (SIK2) Inhibitors | ARRIEN PHARMACEUTICALS LLC | 2016-03-24 | — | — | US | disclosed |
| US-9260426-B2 | Substituted 1H-pyrrolo [2, 3-b] pyridine and 1H-pyrazolo [3, 4-b] pyridine derivatives as salt inducible kinase 2 (SIK2) inhibitors | ARRIEN PHARMACEUTICALS LLC (US) | 2016-02-16 | — | — | US | disclosed |
| US-9260426-B2 | Substituted 1H-pyrrolo [2, 3-b] pyridine and 1H-pyrazolo [3, 4-b] pyridine derivatives as salt inducible kinase 2 (SIK2) inhibitors | ARRIEN PHARMACEUTICALS LLC (US) | 2016-02-16 | — | — | US | disclosed |
| US-9260426-B2 | Substituted 1H-pyrrolo [2, 3-b] pyridine and 1H-pyrazolo [3, 4-b] pyridine derivatives as salt inducible kinase 2 (SIK2) inhibitors | ARRIEN PHARMACEUTICALS LLC (US) | 2016-02-16 | — | — | US | disclosed |
| EP-2931722-A1 | SUBSTITUTED 1H-PYRROLO [2,3-B]PYRIDINE AND 1H-PYRAZOLO [3, 4-B]PYRIDINE DERIVATIVES AS SALT INDUCIBLE KINASE 2 (SIK2) INHIBITORS | Arrien Pharmaeuticals LLC (US) | 2015-10-21 | — | — | EP | disclosed |
| US-20140256704-A1 | Substituted 1H-Pyrrolo [2, 3-b] pyridine and 1H-Pyrazolo [3, 4-b] pyridine Derivatives as Salt Inducible Kinase 2 (SIK2) Inhibitors | ARRIEN PHARMACEUTICALS LLC (US) | 2014-09-11 | — | — | US | disclosed |
| US-20140256704-A1 | Substituted 1H-Pyrrolo [2, 3-b] pyridine and 1H-Pyrazolo [3, 4-b] pyridine Derivatives as Salt Inducible Kinase 2 (SIK2) Inhibitors | ARRIEN PHARMACEUTICALS LLC (US) | 2014-09-11 | — | — | US | disclosed |
| US-20140256704-A1 | Substituted 1H-Pyrrolo [2, 3-b] pyridine and 1H-Pyrazolo [3, 4-b] pyridine Derivatives as Salt Inducible Kinase 2 (SIK2) Inhibitors | ARRIEN PHARMACEUTICALS LLC (US) | 2014-09-11 | — | — | US | disclosed |
| WO-2014093383-A1 | SUBSTITUTED 1H-PYRROLO [2,3-B] PYRIDINE AND 1H-PYRAZOLO [3, 4-B] PYRIDINE DERIVATIVES AS SALT INDUCIBLE KINASE 2 (SIK2) INHIBITORS | ARRIEN PHARMACEUTICALS LLC (US) | 2014-06-19 | — | — | WO | disclosed |
| WO-2014093383-A1 | SUBSTITUTED 1H-PYRROLO [2,3-B] PYRIDINE AND 1H-PYRAZOLO [3, 4-B] PYRIDINE DERIVATIVES AS SALT INDUCIBLE KINASE 2 (SIK2) INHIBITORS | ARRIEN PHARMACEUTICALS LLC (US) | 2014-06-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160090382-A1 | Substituted 1 H-Pyrrolo [2, 3-b] pyridine and 1 H-Pyrazolo [3, 4-b] pyridine Derivatives as Salt Inducible Kinase 2 (SIK2) Inhibitors | SIK2, SIK1, SIK3 | BTK 505/4885ITK 267/4885MAP4K1 55/4885 |
| US-20160081989-A1 | Substituted 1 H-Pyrrolo [2, 3-b] pyridine and 1 H-Pyrazolo [3, 4-b] pyridine Derivatives as Salt Inducible Kinase 2 (SIK2) Inhibitors | SIK2, SIK1, SIK3 | BTK 505/4885ITK 267/4885MAP4K1 55/4885 |
| US-20140256704-A1 | Substituted 1H-Pyrrolo [2, 3-b] pyridine and 1H-Pyrazolo [3, 4-b] pyridine Derivatives as Salt Inducible Kinase 2 (SIK2) Inhibitors | SIK2, SIK1, SIK3 | BTK 492/4885ITK 336/4885MAP4K1 60/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.